Comment on “Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/releasing hormone antagonist in six trials”

24 10 2013

To the Editor:

I read with great interest and attention the original article published recently by Griesinger et al. (1) entitled “Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/releasing hormone antagonist in six trials.” In this article, Griesinger et al. conclude that a progesterone (P) elevation > 1.5 ng/mL on the day of hCG administration is associated with a lower ongoing pregnancy rate (OPR) in the general population, but not in patients with a high ovarian response, defined as an oocyte yield > 18 oocytes.

These authors performed excellent statistical work, pooling data from six multicenter randomized controlled trials relatively similar in their design, and presented the results as if all came from one single study. However, the study deserves several comments that question the unequivocal conclusion that is presented even in the title of the manuscript. Read the rest of this entry »





Progesterone administration route in GnRH antagonist cycles

9 04 2010

To the Editor:

We read interest the paper of Kahraman et al. comparing the effectiveness of vaginal and intramuscular progesteron as luteal phase support among women undergoing IVF with intracytoplasmic sperm injection (ICSI) with gonadotropin-releasing hormone (GnRH) antagonist (1). Read the rest of this entry »





Ovarian steroid hormones differentially regulate thrombospondin-1 expression

12 03 2010

To the Editor:

We read with great interest the article of Tan et al. (1) which reported that thrombospodin-1 (TSP-1), a multifunctional extracellular naturally occurring angiostatic protein is differentially regulated by ovarian steroids. Although it is of great clinical value to understand the mechanism(s) involved in TSP-1 regulation by ovarian steroidal hormones especially in relation to how it is involved in endometriosis. However, there are some points we would like to raise regarding the study of Tan et al. (1). Read the rest of this entry »





Questions regarding the progesterone pharmacokinetic study.

13 10 2009

To the Editor:

We disagree with the results of the trial by Blake et al. (1) with regard to the pharmacokinetics of Crinone and Endometrin. Read the rest of this entry »





Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation

26 11 2008

To the Editor:

I read with interest the article by Doody, et al (1). The literature support for the need for luteal support in IVF was presented by Daya and Gunby.(2) A recent reanalysis (3) of this meta-analysis suggests the use of vaginal progesterone to be as effective as IM Progesterone. In order to better understand this publication I seek a few points of clarification. Read the rest of this entry »